Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan

Clinical trial NCT06833268 · COMPLETED

Trial details

NCT number: NCT06833268
Sponsor: Daiichi Sankyo
Status: COMPLETED
Study type: OBSERVATIONAL

HER2-positive Breast Cancer

Start date: 2025-01-20
Primary completion: 2025-06-16
Enrollment: 228

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.